Get the Stockscreener App
0.9833
9.03%
0.0814
After Hours:
.96
-0.0233
-2.37%
Humacyte Inc stock is traded at $0.9833, with a volume of 5.99M.
It is up +9.03% in the last 24 hours and up +51.28% over the past month.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
See More
Previous Close:
$0.9019
Open:
$0.9052
24h Volume:
5.99M
Relative Volume:
0.90
Market Cap:
$218.31M
Revenue:
$2.04M
Net Income/Loss:
$-43.21M
P/E Ratio:
-4.7571
EPS:
-0.2067
Net Cash Flow:
$-105.93M
1W Performance:
+19.91%
1M Performance:
+51.28%
6M Performance:
-24.94%
1Y Performance:
-20.06%
1-Day Range:
$0.88
$0.9924
1-Week Range:
$0.8001
$0.9924
52-Week Range:
$0.5469
$2.93
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919-313-9633
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
0.9833 | 200.24M | 2.04M | -43.21M | -105.93M | -0.2067 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-27-25 | Initiated | Barclays | Overweight |
| May-14-25 | Resumed | H.C. Wainwright | Buy |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-11-23 | Initiated | H.C. Wainwright | Buy |
| Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
| Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
| Oct-29-21 | Initiated | Cowen | Outperform |
| Sep-24-21 | Initiated | Oppenheimer | Outperform |
| Sep-22-21 | Initiated | BTIG Research | Buy |
| Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
Humacyte, Inc. (HUMA) stock sinks as market gains: Here's why - MSN
Humacyte (HUMA) Motion to Dismiss Ruling Keeps Key Securities Claims Alive - TipRanks
Humacyte, Inc. (NASDAQ:HUMA) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Humacyte, Inc. (HUMA) surpasses market returns: Some facts worth knowing - MSN
HUMA Should I Buy - Intellectia AI
Humacyte, Inc. (HUMA) Gains As Market Dips: What You Should Know - MSN
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - TMX Newsfile
Humacyte, Inc. (HUMA) Surpasses Market Returns: Some Facts Worth Knowing - Yahoo Finance
Humacyte regains ex-US rights to Symvess from Fresenius Medical Care - MSN
Humacyte estimates delayed emergency care in vascular trauma puts life and limb at elevated risk - Traders Union
H.C. Wainwright Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $3 - Moomoo
Humacyte stock price target reiterated at $3 by H.C. Wainwright - Investing.com Australia
Barclays Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $1.5 - Moomoo
HUMA Stock Price, Quote & Chart | HUMACYTE INC (NASDAQ:HUMA) - ChartMill
Humacyte Highlights Dialysis Access Data; Women Show Strong ATEV Edge, V012 Results Due in June - MarketBeat
Humacyte (HUMA) price target decreased by 31.82% to 5.46 - MSN
TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $1 - Moomoo
Humacyte (NASDAQ: HUMA) 2026 proxy adds share increase vote - Stock Titan
D. Boral Capital Reaffirms "Buy" Rating for Humacyte (NASDAQ:HUMA) - MarketBeat
BTIG Research Reaffirms Buy Rating for Humacyte (NASDAQ:HUMA) - MarketBeat
Humacyte Q4 2025 earnings preview - MSN
Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026 - The Manila Times
Humacyte webcast tackles dialysis access with Phase 3 results due - Stock Titan
Humacyte Expands Commercial and Business Development Opportunities through Realignment of Ex-U.S. Rights to Symvess - marketscreener.com
Humacyte (HUMA) takes ex-U.S. Symvess control as Fresenius retains 8.4% stake - Stock Titan
Humacyte Stock (HUMA) Opinions on Symvess Rights Realignment - Quiver Quantitative
Humacyte regains ex-U.S. rights to Symvess from Fresenius By Investing.com - Investing.com Australia
Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc.HUMA - PR Newswire
Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Humacyte Is Maintained at Buy by D. Boral Capital - Moomoo
Humacyte gets global rights to Symvess from Fresenius (HUMA) - Seeking Alpha
FMS Partners with Humacyte to Restructure Symvess Distribution R - GuruFocus
Humacyte Realigns Ex-U.S. Rights to Symvess with Fresenius Medical Care to Accelerate International Commercial Expansion - Minichart
Humacyte Regains Global Rights to Symvess Vascular Graft - TipRanks
Humacyte Marketing Authorization for Symvess acellular vessel accepted by Israel Ministry of Health - Traders Union
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):